Parkinson's disease, primates, and gene therapy: vive la différence?
作者信息
Lewis Travis B, Standaert David G
出版信息
Mov Disord. 2011 Jan;26(1):2-3. doi: 10.1002/mds.23544. Epub 2010 Dec 17.
Abstract
摘要
相似文献
1
Parkinson's disease, primates, and gene therapy: vive la différence?帕金森病、灵长类动物与基因治疗：差异万岁？
Mov Disord. 2011 Jan;26(1):2-3. doi: 10.1002/mds.23544. Epub 2010 Dec 17.
2
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.AAV2-神经生长因子基因治疗（CERE-120）的生物活性：帕金森病和非人灵长类动物大脑之间的差异。
Mov Disord. 2011 Jan;26(1):27-36. doi: 10.1002/mds.23442. Epub 2010 Nov 18.
3
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.向特发性帕金森病患者脑内注射CERE-120（腺相关病毒2型-神经营养因子）的安全性和耐受性：一项开放标签的I期试验。
Lancet Neurol. 2008 May;7(5):400-8. doi: 10.1016/S1474-4422(08)70065-6. Epub 2008 Apr 2.
4
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.AAV2-神经生长因子基因治疗帕金森病：一项双盲、随机、对照试验。
Lancet Neurol. 2010 Dec;9(12):1164-1172. doi: 10.1016/S1474-4422(10)70254-4. Epub 2010 Oct 20.
5
Gene therapy for Parkinson's disease: do we have the cure?帕金森病的基因治疗：我们找到治愈方法了吗？
Lancet Neurol. 2010 Dec;9(12):1142-1143. doi: 10.1016/S1474-4422(10)70256-8.
6
Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease.将神经营养因子作为治疗与年龄相关的神经退行性疾病的手段：在帕金森病中开发和证明 AAV-neurturin（CERE-120）的“临床概念验证”。
Neurobiol Aging. 2013 Jan;34(1):35-61. doi: 10.1016/j.neurobiolaging.2012.07.018. Epub 2012 Aug 24.
7
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial.脑源性神经营养因子经壳核和黑质脑内给药治疗帕金森病的双盲、随机、对照研究。
Ann Neurol. 2015 Aug;78(2):248-57. doi: 10.1002/ana.24436. Epub 2015 Jun 10.
8
Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease.基于数据的神经外科基因疗法在帕金森病中的应用演变。
J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1210-1218. doi: 10.1136/jnnp-2020-322904. Epub 2020 Jul 30.
9
Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease.神经胶质细胞源性神经营养因子基因治疗晚期帕金森病患者的长期尸检研究。
Brain. 2020 Mar 1;143(3):960-975. doi: 10.1093/brain/awaa020.
10
The delivery of tyrosine hydroxylase accelerates the neurorestoration of Macaca Rhesus model of Parkinson's disease provided by Neurturin.酪氨酸羟化酶的传递加速了 Neurturin 提供的猕猴帕金森病神经修复。
Neurosci Lett. 2012 Aug 22;524(1):10-5. doi: 10.1016/j.neulet.2012.06.063. Epub 2012 Jul 2.
引用本文的文献
1
How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?重组腺相关病毒-α-突触核蛋白和丝状α-突触核蛋白模型如何促进我们对帕金森病的理解？
J Neurochem. 2016 Oct;139 Suppl 1(Suppl 1):131-155. doi: 10.1111/jnc.13627. Epub 2016 May 4.
2
Formation of α-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes.轴突中α-突触核蛋白路易神经突样聚集体的形成会阻碍不同内体的运输。
Mol Biol Cell. 2014 Dec 15;25(25):4010-23. doi: 10.1091/mbc.E14-02-0741. Epub 2014 Oct 8.
本文引用的文献
1
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.AAV2-神经生长因子基因治疗帕金森病：一项双盲、随机、对照试验。
Lancet Neurol. 2010 Dec;9(12):1164-1172. doi: 10.1016/S1474-4422(10)70254-4. Epub 2010 Oct 20.
2
Target validation: the Parkinson disease perspective.靶点验证：帕金森病视角
Dis Model Mech. 2010 May-Jun;3(5-6):259-62. doi: 10.1242/dmm.004192.
3
Axonal transport defects in neurodegenerative diseases.神经退行性疾病中的轴突运输缺陷
J Neurosci. 2009 Oct 14;29(41):12776-86. doi: 10.1523/JNEUROSCI.3463-09.2009.
4
Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.AAV2-GDNF 基因转移到老龄和帕金森病恒河猴多巴胺能黑质纹状体通路的安全性评估。
Hum Gene Ther. 2009 Dec;20(12):1627-40. doi: 10.1089/hum.2009.103.
5
Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.腺相关病毒2型介导的神经营养因子向猴黑质纹状体系统递送1年后的表达、生物活性及安全性支持CERE-120用于帕金森病治疗
Neurosurgery. 2009 Apr;64(4):602-12; discussion 612-3. doi: 10.1227/01.NEU.0000340682.06068.01.
6
Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity.黑质纹状体区域腺相关病毒介导的胶质细胞源性神经营养因子过表达在年龄相关性肥胖大鼠模型中诱导显著体重减轻。
Mol Ther. 2009 Jun;17(6):980-91. doi: 10.1038/mt.2009.45. Epub 2009 Mar 10.
7
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.向特发性帕金森病患者脑内注射CERE-120（腺相关病毒2型-神经营养因子）的安全性和耐受性：一项开放标签的I期试验。
Lancet Neurol. 2008 May;7(5):400-8. doi: 10.1016/S1474-4422(08)70065-6. Epub 2008 Apr 2.
8
Design of clinical trials of gene therapy in Parkinson disease.
Exp Neurol. 2008 Jan;209(1):41-7. doi: 10.1016/j.expneurol.2007.08.012. Epub 2007 Aug 31.
9
Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.帕金森病患者单侧壳核内注射胶质细胞源性神经营养因子：1年治疗及1年撤药后的反应
J Neurosurg. 2007 Apr;106(4):614-20. doi: 10.3171/jns.2007.106.4.614.
10
Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.小鼠黑质中α-突触核蛋白靶向过表达诱导多巴胺能神经元丢失及伴侣蛋白mRNA上调。
J Neurochem. 2007 Mar;100(6):1449-57. doi: 10.1111/j.1471-4159.2006.04310.x. Epub 2007 Jan 4.
Zotero 插件